Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Early Diagnosis of Pancreatic Cancer-Network Collaborative Studies

Early Diagnosis of Pancreatic Cancer-Network Collaborative Studies

196
UNKNOWN
G.I. and Other Associated Cancers Research Group

Determining and quantifying the types of mucin core proteins to which CA19-9 is attached will result in assays with improved performance characteristics compared to CA19-9 alone.

Specific Aim 1) Utilize newly developed and to be developed antibodies against the mucin core proteins MUC1, MUC4, and MUC17 to develop an improved serum assay for pancreatic adenocarcinoma. Specific Aim 2) Develop and utilize a set of monoclonal antibodies that recognize serum forms of distinct mucin core proteins, utilize these to improve the diagnostic capability of the CA 19-9 type tests for nonmalignant, premalignant and malignant lesions of the pancreas, and evaluate the capability of the test to discriminate pancreatic cancer from other adenocarcinomas.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 06/30/2017

The next EDRN Steering Committee Meeting is from September 12-14, 2017, in Seattle WA. Please click here to register and find out more information about the meeting.

Announcement



EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.